The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Alzheimers Dement. 2017 May;13(5):561-571. doi: 10.1016/j.jalz.2016.10.006. Epub 2016 Dec 5.


Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.

Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.

Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression.

Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

Keywords: Alzheimer's disease; Amyloid phenotyping; Brain Health Registry; Centiloid method; Clinical trial biomarkers; Functional connectivity; Tau imaging.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / diagnostic imaging*
  • Alzheimer Disease / physiopathology*
  • Biomarkers / cerebrospinal fluid
  • Brain / diagnostic imaging
  • Clinical Trials as Topic*
  • Disease Progression
  • Humans
  • Magnetic Resonance Imaging
  • Neuroimaging*
  • Positron-Emission Tomography
  • Radionuclide Imaging


  • Biomarkers